Takeda launches CINRYZE in India for hereditary angioedema patients
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
The designation recognizes Seeq's expertise in enabling faster insights and better business outcomes for life sciences customers, including Bristol Myers Squibb, with advanced analytics innovations.
This partnership stemmed from a successful customer-supplier relationship spanning several years.
The investment will enable the company to enter European markets as well as enhance margins in current markets
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
Silodosin capsules treat signs and symptoms of an enlarged prostate gland
The proceeds of the issue has been/will be reinvested in the company and to meet its own business requirements.
The funds raised through the issue will be utilised to meet the working capital requirements to fund the company's expansion plans, entering new geographies and for general corporate purposes
Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio
Subscribe To Our Newsletter & Stay Updated